Table 2.
Bone turnover changes (mean ± SD)
| Treatment groups | Osteocalcin (µg/mL) | CTX-1 (ng/mL) | MS/BS (%) | BFR/BS (µm3/µm2/day) | Oc/BS (number/mm) |
|---|---|---|---|---|---|
| Male | |||||
| Male | 5.1 ± 1.6 | 23 ± 1.7 | 24 ± 6.9 | 0.45 ± 0.1 | 0.60 ± 0.1 |
| Male + β-ecdysone | 6.5 ± 1.5 | 21 ± 5.0 | 33 ± 1.1‡ | 0.61 ± 0.2‡ | 0.59 ± 0.1 |
| ORX + vehicle | 13 ± 1.4* | 26 ± 2.5 | 26 ± 4.1 | 0.61 ± 0.2* | 0.66 ± 0.1 |
| ORX + β-Ecdysone | 15 ± 1.2* | 25 ± 2.7 | 28 ± 4.3 | 0.69 ± 0.1 | 0.62 ± 0.1 |
| Female | |||||
| Female | 12 ± 2.6† | 19 ± 3.4 | 26 ± 4.8 | 0.64 ± 0.2† | 0.57 ± 0.1 |
| Female + β-ecdysone | 12 ± 1.5† | 16 ± 3.0 | 35 ± 10.3 | 0.86 ± 0.3 | 0.61 ± 0.1 |
| OVX + vehicle | 14 ± 3.1 | 24 ± 1.6* | 29 ± 8.3 | 0.66 ± 0.2 | 0.91 ± 0.1* |
| OVX + β-ecdysone | 14 ± 1.2 | 20 ± 2.3‡ | 34 ± 9.1 | 0.82 ± 0.2‡ | 0.78 ± 0.0‡ |
* p < 0.05 for ORX/OVX versus sham; †p < 0.05 for sex difference; ‡p < 0.05 treatment effect within the same sex; MS/BS = mineralizing surface; BFR/BS = surface-based bone formation rate; Oc/BS = osteoclast/bone surface; ORX = orchiectomy; OVX = ovariectomy.